Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review.

ABSTRACT: Lung cancer is one of the most common malignant tumors and it is the leading cause of cancer-related mortality worldwide. For early-stage Non-Small Cell Lung Cancer (NSCLC), surgical resection is the treatment of choice, but the 5-year survival is still unsatisfying, ranging from 60% to 36% depending on the disease stage. Multimodality treatment with adjuvant chemotherapy did not lead to clinically relevant results, improving survival rates by only 5%. Recently, immune checkpoint inhibitors (ICIs) are being studied as neoadjuvant treatment for resectable NSCLC too, after the satisfactory results obtained in stage IV disease. Several clinical trials are evaluating the safety and feasibility of neoadjuvant immunotherapy and their early findings suggest that ICIs could be better tolerated tha

SUBMITTER: Gatteschi L 

PROVIDER: S-EPMC8539920 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature